When to Start PCT After a Steroid Cycle
When to Start PCT After a Steroid Cycle
When to start PCT after a steroid cycle is not answered by a fixed number of days — it is answered by the pharmacokinetics of the specific compounds used. Beginning post-cycle therapy while suppressive androgens are still active in serum produces no benefit: the hypothalamic-pituitary axis cannot respond to selective estrogen receptor modulators until exogenous testosterone has cleared to a level that permits natural LH and FSH signaling to resume. This guide covers ester half-life math, compound-specific wait windows, individual factors that shift those windows, and the bloodwork markers that confirm readiness to begin post-cycle therapy.
When to Start PCT — 3 Core Principles
Ester Half-Life Drives Timing
When to start PCT is determined first by which ester was used. Short esters like propionate and acetate clear in days, allowing PCT to begin two to three days after the last injection. Long esters like enanthate and cypionate require a 14-day minimum wait. Nandrolone decanoate requires three to four weeks. Testosterone undecanoate requires the longest wait of any common preparation — four to six weeks minimum, confirmed by bloodwork.
Starting Too Early Wastes PCT
If exogenous testosterone is still pharmacologically active in serum, SERMs cannot meaningfully raise LH or FSH. The HPTA continues to read the androgenic environment as sufficient and suppresses GnRH pulsatility regardless of SERM use. Knowing when to start PCT means waiting until the suppressive compound has cleared enough for the hypothalamic-pituitary axis to receive and respond to signaling again.
Bloodwork Is the Reliable Signal
Calculated clearance windows are population-level estimates based on published half-life data. Individual clearance rates vary. Bloodwork — specifically total testosterone, LH, and FSH — shows whether the axis is still fully suppressed or has begun spontaneous recovery, and is the most reliable confirmation that when to start PCT has been timed correctly for that individual.
What This Guide Covers on PCT Timing
Covered in This Guide
- Why PCT timing depends on ester pharmacokinetics
- Half-life and clearance math for common esters
- Wait windows for short, medium, and long esters
- Oral-only cycle timing considerations
- Nandrolone and trenbolone clearance differences
- 6 individual factors that affect PCT start timing
- Role of bloodwork in confirming readiness
- Common timing mistakes and their consequences
Not Covered Here
- Nolvadex, Clomid, or HCG dosing protocols
- Blast-and-cruise or TRT transition decisions
- SARM suppression and recovery (different profile)
- Female hormonal recovery after cycle use
- Specific fertility restoration protocols
This guide is part of the PCT section of MuscleScience.org. For the foundational explanation of why suppression occurs, see Why Steroids Cause Testosterone Suppression. For what the axis experiences during recovery, see How Hormonal Recovery Works After Steroids. For bloodwork markers during PCT, see Bloodwork Before and After PCT.
What “Waiting to Start PCT” Actually Means
The phrase “when to start PCT” is often used as if it refers to starting a drug on a specific day. In practice, the question is about something more fundamental: when has the suppressive compound cleared enough for the hypothalamic-pituitary axis to begin receiving and responding to external signaling again.
As long as exogenous testosterone — or any other suppressive androgen — remains active in serum above a meaningful threshold, the hypothalamus continues to read the androgenic environment as sufficient. It reduces or stops GnRH pulsatility. The pituitary receives less GnRH and produces less LH and FSH. The Leydig cells, without LH stimulation, do not produce endogenous testosterone. Selective estrogen receptor modulators — Nolvadex and Clomid — work by blocking estrogen receptors at the hypothalamus and pituitary, removing estrogen’s negative feedback and prompting GnRH and subsequently LH and FSH output. But this mechanism only functions if the primary suppressive signal — high androgenic activity from exogenous testosterone — is no longer dominant.
When to start PCT, therefore, is the point at which exogenous androgens have cleared sufficiently that SERMs can actually reach and activate the feedback pathway they are designed to affect. Starting SERMs while a long ester is still active in serum does not meaningfully raise LH or FSH. It consumes the drug in a window where it cannot produce the intended effect. The wait period before PCT begins is not a delay — it is a prerequisite for the intervention to work at all.
This is also why different compounds require different wait periods. The ester determines how quickly the compound clears. When to start PCT is a different calculation for testosterone propionate than it is for testosterone enanthate, nandrolone decanoate, or testosterone undecanoate.
Why “End of Cycle” Is Not the Same as Clearance
Many people define the end of a cycle as the last injection. The pharmacokinetics of testosterone esters make clear that this is not when androgen exposure ends. After the last injection of testosterone enanthate, serum testosterone remains supraphysiological for several days and above the suppressive threshold for up to two weeks. The cycle may have ended on paper, but the HPTA is still fully suppressed. Knowing when to start PCT requires understanding how long that window of ongoing suppressive exposure actually lasts — and that varies enormously by compound. See What Are Anabolic Steroids and Injectable vs Oral Steroids for background on how ester structure affects pharmacokinetics.
Ester Half-Lives and the Wait Window Per Compound
Each testosterone ester — and each non-testosterone androgen — has a documented pharmacokinetic profile. The half-life of the ester determines how quickly serum levels fall after the last injection. The conventional estimate for full clearance uses five half-lives, the point at which approximately 97% of the compound has been eliminated. This is the basis for calculating when to start PCT for any given compound.
The contrast between short-ester and long-ester preparations is significant and has direct practical consequences. Nandrolone decanoate’s half-life of approximately 15 days means full clearance takes over ten weeks — far beyond the 14-day window that covers testosterone enanthate. The compound in the stack with the longest ester sets the timing floor for when to start PCT.
| Compound | Ester | Half-Life | ~5 Half-Lives | Typical PCT Wait |
|---|---|---|---|---|
| Testosterone Propionate | Propionate | 2–3 days | 10–15 days | 2–3 days after last injection |
| Testosterone Enanthate | Enanthate | 4–5 days | 20–25 days | 14 days after last injection |
| Testosterone Cypionate | Cypionate | 5–6 days | 25–30 days | 14 days after last injection |
| Nandrolone Decanoate | Decanoate | ~15 days | ~75 days | 3–4 weeks after last injection |
| Trenbolone Enanthate | Enanthate | 5–7 days | ~35 days | 14 days after last injection |
| Trenbolone Acetate | Acetate | 1–2 days | 5–10 days | 2–3 days after last injection |
| Testosterone Undecanoate (injectable) | Undecanoate | ~34 days | ~5 months | 4–6 weeks minimum; bloodwork required |
Half-life estimates reflect published pharmacokinetic data. Individual clearance rates vary based on metabolism, body composition, injection volume, and formulation. These figures represent approximate guidance, not fixed clinical standards. When in doubt, confirm with bloodwork before starting PCT.
Why the Longest Ester in the Stack Determines Timing
When multiple compounds are used in the same cycle, the question of when to start PCT is answered by the compound with the longest ester — not the shortest. If a cycle includes both testosterone propionate and nandrolone decanoate, the propionate will clear in a few days while the decanoate may still be suppressive for three to four weeks. PCT cannot begin until both are below the meaningful suppressive threshold. Stacking long esters alongside short ones does not make the long ester clear faster — the slowest compound in the cycle sets the timing floor for when to start PCT.
How the Five-Half-Life Rule Applies to PCT Timing
The five-half-life model gives a working estimate for compound clearance. At five half-lives, approximately 97% of the active compound has been eliminated from serum. This does not mean the compound is completely undetectable — sensitive assays can identify trace levels beyond this point — but it represents the threshold at which the suppressive androgenic signal has dropped far enough for the HPTA to begin responding to its own feedback environment again.
Applying this to a practical example: a cycle using testosterone enanthate at 500 mg per week ends with the last injection on a given day. Testosterone enanthate has a half-life of approximately four to five days. The conventional recommendation of 14 days for enanthate-based cycles reflects roughly 2.5 to 3.5 half-lives — a point where serum levels have dropped substantially but not necessarily to the full five-half-life threshold. This is why 14 days functions as a practical minimum rather than a guarantee of complete clearance.
The five-half-life calculation is an approximation, not a clinical ceiling. Individual metabolism, body composition, injection volume, specific formulation, and consistency of dosing during the cycle all affect actual clearance speed. Confirming when to start PCT with confidence — rather than working from a fixed-day estimate — requires bloodwork: specifically total testosterone, LH, and FSH.
What Bloodwork Tells You About PCT Readiness
If total testosterone remains significantly above the natural range at the two-week mark after a long-ester cycle, clearance is slower than average and the PCT start should be pushed further back. If LH and FSH are still fully suppressed at or near zero, the HPTA has not yet begun signaling independently, which means SERMs have no active feedback loop to amplify. Conversely, if LH and FSH show even modest spontaneous recovery before PCT begins, it confirms the axis is responding and the timing window is appropriate. See Bloodwork Before and After PCT for a full breakdown of which markers to test and how to read them during recovery.
Key point: The five-half-life rule estimates when serum levels of the compound have dropped to approximately 3% of peak value. At this point, suppressive androgenic signaling is low enough for the HPTA to begin responding. This is the scientific basis for the timing windows in the clearance table above — and for understanding when to start PCT in any specific situation.
Oral-Only and Short-Ester Cycles — When PCT Timing Compresses
Not every cycle uses long-ester injectables. Oral-only cycles — Dianabol, Anavar, Winstrol — and injectable cycles built around short esters like testosterone propionate or trenbolone acetate have significantly faster clearance profiles. When to start PCT after these cycles follows a compressed timeline compared to the 14-day standard for enanthate or cypionate.
Oral anabolic steroids carry no ester. Their active half-lives are measured in hours: methandrostenolone (Dianabol) has a half-life of approximately three to six hours; oxandrolone (Anavar) approximately nine hours; stanozolol (Winstrol) approximately nine hours in oral form. At five half-lives, these compounds are functionally cleared within one to three days of the last dose. Most conventional recommendations place the starting point at 24 to 48 hours after the final oral dose.
The practical concern with oral-only cycles is not clearance speed — it is the depth of suppression that built up over the course of the cycle. Orals suppress the HPTA through the same negative feedback mechanism as injectables. A 12-week oral cycle may produce significant LH and FSH suppression even though the compound clears rapidly. When to start PCT is answerable quickly in terms of clearance, but the recovery process after an oral-only cycle can still take weeks depending on how long and how deeply the axis was suppressed.
Testosterone Propionate and Trenbolone Acetate
Short-ester injectables clear faster than long-ester versions of the same compound. Testosterone propionate, with a half-life of approximately two to three days, reaches the five-half-life clearance threshold within roughly ten to fifteen days of the last injection. The conventional wait before when to start PCT with propionate is two to three days after the last injection — significantly shorter than the 14-day standard for enanthate.
Trenbolone acetate follows a similar pattern, with a half-life of one to two days. When to start PCT after a trenbolone acetate cycle can begin two to three days after the last injection, though the suppressive potency of trenbolone means the HPTA may be more deeply suppressed than after an equivalent testosterone-only cycle. The short-ester advantage in terms of PCT timing comes with a tradeoff: blood levels fall more abruptly post-cycle, which can mean a more pronounced symptomatic gap between cycle end and SERM-driven recovery. See Fertility and Suppression on Steroids for how androgenic potency affects suppression depth and fertility recovery.
Nandrolone, Undecanoate, and Extended Wait Windows
Some compounds create substantially longer clearance windows than standard testosterone esters, and when to start PCT in these cases requires a different calculation — one that often catches users off guard because the compounds are stacked alongside shorter-ester testosterone.
Nandrolone Decanoate (Deca-Durabolin)
Nandrolone decanoate is one of the most commonly stacked compounds after testosterone enanthate, and it has one of the longest clearance profiles in common use. The decanoate ester has a half-life of approximately 15 days. At five half-lives, this places full clearance at roughly 75 days — over ten weeks — after the last injection. When to start PCT after a cycle that includes nandrolone decanoate cannot follow the standard 14-day testosterone enanthate timeline. The nandrolone component will still be suppressive at the two-week mark.
The conventional approach for deca-inclusive cycles is to stop nandrolone several weeks before the end of the testosterone component — sometimes four to six weeks earlier — so that the nandrolone has more time to clear before the overall cycle ends. When to start PCT is then timed from the last testosterone injection at the standard 14-day wait. Without this staggered approach, the nandrolone alone can delay when to start PCT by three to four weeks beyond the testosterone clearance point.
Testosterone Undecanoate Injectable (Nebido)
Injectable testosterone undecanoate presents the most extreme clearance timeline of any commonly used testosterone preparation. Clinical pharmacokinetic studies established its half-life at approximately 34 days for intramuscular administration. At five half-lives, full clearance requires approximately five months. When to start PCT after a cycle built around injectable undecanoate is therefore not a 14-day or even a 4-week calculation — it requires six weeks as an absolute minimum, with bloodwork used to confirm actual serum clearance before PCT begins.
This compound is used primarily in TRT and clinical hypogonadism management rather than cycle-based athletic use. Anyone requiring PCT after undecanoate-based suppression should treat the wait window as substantially longer than any short or medium ester cycle, and consult TRT Bloodwork alongside this guide for the relevant hormonal context. The article on Total vs Free Testosterone is useful for interpreting bloodwork during the extended clearance period.
Trenbolone Enanthate
Trenbolone enanthate carries the enanthate ester and therefore has a half-life similar to testosterone enanthate — five to seven days. When to start PCT after a trenbolone enanthate cycle uses the same 14-day wait as testosterone enanthate. The distinction from the acetate version is meaningful: trenbolone acetate allows PCT to begin in two to three days, while trenbolone enanthate requires the full two-week wait. Because trenbolone is a potent suppressor, the depth of HPTA suppression after tren use may be greater than after equivalent testosterone doses, even when the clearance timing is similar. Bloodwork before starting PCT is particularly advisable after any trenbolone cycle.
6 Factors That Affect When to Start PCT for Any Individual
Clearance tables and half-life math provide population-level estimates. Individual responses to both suppression and clearance vary. When to start PCT in practice may need to be adjusted based on the factors below, which shift the timing window or the difficulty of recovery — even when ester clearance timing itself is fixed.
- Factor 01
Cycle Length
A 6-week cycle suppresses the HPTA less deeply and for a shorter duration than a 20-week cycle using the same compounds and doses. Longer cycles cause more sustained suppression of GnRH pulsatility and produce deeper Leydig cell desensitization. When to start PCT does not change based on cycle length — clearance timing is still ester-driven — but the difficulty of recovery after PCT begins is significantly greater after longer cycles. Research on anabolic steroid-induced hypogonadism identifies cycle duration as one of the primary predictors of suppression severity and recovery difficulty.
- Factor 02
Compound Dose
Higher doses of exogenous testosterone produce deeper suppression and may produce slightly longer effective suppressive windows even after clearance has technically begun, because the starting serum concentration is higher. A cycle run at 1,000 mg per week will produce higher peak serum levels than one at 300 mg per week. When to start PCT is the same in terms of the five-half-life calculation, but the absolute serum level at the two-week mark after a high-dose cycle may still be above the suppressive threshold even when clearance math suggests otherwise.
- Factor 03
Individual Metabolism and Clearance Rate
Liver function, body fat percentage, injection site, and individual pharmacokinetic variation all influence how quickly a compound clears. Half-life values in published studies reflect means and ranges, not fixed values for every individual. When to start PCT based on a 14-day estimate for enanthate will be accurate for most people, but some individuals with slower clearance may still show suppressive serum levels at two weeks, while others may clear faster. This variation is one of the strongest arguments for using bloodwork to confirm PCT readiness rather than calendar math alone.
- Factor 04
Age
Natural testosterone production and HPTA responsiveness decline with age. Older users may have slower spontaneous recovery after suppression even when the timing of when to start PCT is correct. The hypothalamic and pituitary components of the axis may respond more slowly to SERM-driven signaling in men over 40 compared to younger users. This does not change when to start PCT — it changes the difficulty and duration of the recovery process after PCT begins. Baseline bloodwork from before the cycle is particularly important for older users to contextualize what recovery means in their individual case. See Blood Tests Before Steroids for pre-cycle baseline guidance.
- Factor 05
Previous Cycles and Prior Suppression History
Repeated suppression and recovery cycles appear to reduce HPTA resilience over time. Users with many prior cycles may find that the axis takes longer to recover even when when to start PCT is timed correctly. Prior incomplete recoveries — situations where full LH, FSH, and testosterone normalization was never confirmed before the next cycle began — compound this effect and make the recovery arc less predictable from clearance math alone. Confirming hormonal baseline between cycles via bloodwork is the only way to track cumulative suppression history accurately.
- Factor 06
Fertility Goals
When to start PCT carries different urgency depending on whether restoring fertility within a specific timeframe is a priority. Spermatogenesis recovers more slowly than serum testosterone — FSH must be present for an extended period before sperm production resumes. Users with active fertility goals may need to time when to start PCT more carefully, begin earlier in compound clearance where pharmacokinetics allow, and in some cases consult a reproductive endocrinologist alongside this guide. See Fertility and Suppression on Steroids for the full picture of how suppression affects sperm production and what recovery involves.
4 Common Mistakes When Deciding When to Start PCT
Most timing errors in PCT fall into predictable patterns. Understanding them helps avoid the two failure modes: starting too early, when suppressive androgens are still active; or starting too late, when spontaneous recovery has stalled and the window for SERM-driven support has narrowed.
- Mistake
Starting PCT the Day After the Last Long-Ester Injection
This is the most common and consequential timing error. After the last injection of testosterone enanthate or cypionate, serum testosterone remains supraphysiological for days and above the suppressive threshold for up to two weeks. Starting a SERM at day one or two post-injection means the HPTA is still fully suppressed by circulating exogenous testosterone. LH and FSH will not meaningfully rise. The drug is consumed in a window where it cannot produce the intended effect. When to start PCT with long esters requires a minimum 14-day wait — not a 24-hour one.
- Mistake
Applying the Same Wait Window to All Compounds
Using the 14-day enanthate standard for every compound regardless of ester is a systematic error. Nandrolone decanoate requires three to four weeks minimum. Testosterone undecanoate requires four to six weeks or longer. Testosterone propionate and trenbolone acetate allow PCT to begin at two to three days post-injection. Treating every compound as if it has the same clearance profile means either starting too early on long-ester cycles or waiting unnecessarily on short-ester cycles. The ester determines the timing — not the compound class or the total weekly dose.
- Mistake
Not Accounting for Nandrolone in the Stack
Users who run testosterone enanthate plus nandrolone decanoate and then apply the standard 14-day wait after the last testosterone injection often begin PCT while nandrolone is still actively suppressing the axis. When to start PCT in a deca-inclusive cycle cannot be timed from the last testosterone shot unless the nandrolone was stopped four to six weeks earlier. Failing to stagger the compounds means the 14-day wait after testosterone ends is not long enough — the decanoate ester is still releasing nandrolone at suppressive concentrations. Bloodwork is especially important in this scenario for confirming readiness. See Bloodwork Before and After PCT for which markers confirm clearance.
- Mistake
Relying Solely on Calendar Math Without Bloodwork
Half-life calculations are population averages. Individual clearance rates vary based on metabolism, injection volume, body composition, and formulation. Calendar math tells you when to start PCT on average — bloodwork tells you whether that estimate was accurate for you specifically. Running LH, FSH, and total testosterone before beginning a SERM protocol removes the guesswork and prevents both premature starts (when the axis is still fully suppressed) and delayed starts (when the axis has already begun spontaneous recovery and the window for SERM support is narrowing). See the Bloodwork & Health Hub for how to interpret these results in context.
External References
- Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. 1999;140(5):414–9. pubmed.ncbi.nlm.nih.gov/10229906
- von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl. 2002;23(3):419–25. pubmed.ncbi.nlm.nih.gov/12002444
- Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–9. pubmed.ncbi.nlm.nih.gov/24636400
- Tom L, Bhasin S, Salameh W, et al. Induction of azoospermia in normal men with combined Nal-Glu GnRH antagonist and testosterone enanthate. J Clin Endocrinol Metab. 1992;75(2):476–83. pubmed.ncbi.nlm.nih.gov/1639948
- Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW, Lipshultz LI. Anabolic steroid induced hypogonadism in young men. J Urol. 2013;190(6):2200–5. pubmed.ncbi.nlm.nih.gov/23764084
When to Start PCT — What the Evidence Shows
When to start PCT is a pharmacokinetic question before it is anything else. The ester attached to the compound determines how quickly active hormone clears from serum. Short esters like propionate and acetate allow PCT to begin within two to three days of the last injection. Medium esters like enanthate and cypionate require a 14-day minimum wait. Long esters like nandrolone decanoate require three to four weeks. Injectable testosterone undecanoate requires the longest wait of commonly used preparations — a minimum of four to six weeks, confirmed by bloodwork.
Individual factors including cycle length, dose, age, metabolism, and prior suppression history all affect the recovery arc after when to start PCT is timed correctly, even if they do not change the ester-driven clearance calculation itself. Bloodwork remains the most reliable tool for confirming that PCT timing is appropriate in any individual case — because half-life math gives averages, not personal values.
The guides below provide surrounding context for a complete picture of post-cycle recovery:
- PCT Library — full hub for all post-cycle therapy guides
- What Is Post-Cycle Therapy — foundational overview of the intervention and its pharmacological basis
- Why Steroids Cause Testosterone Suppression — the mechanism behind HPTA shutdown
- How Hormonal Recovery Works After Steroids — what the axis experiences during the recovery window
- Bloodwork Before and After PCT — which markers to test and how to read them during recovery
- Bloodwork & Health Hub — marker-by-marker reference for monitoring health on cycle and off
- Start Here — site orientation and recommended reading order
For Educational Purposes Only
This article discusses the pharmacokinetics of anabolic steroids and post-cycle therapy timing for educational and harm-reduction purposes. It does not constitute medical advice and is not a substitute for consultation with a qualified physician. The information provided reflects published research and is intended to support informed decision-making, not to encourage or facilitate the use of controlled substances.
MuscleScience.org does not sell any compounds, medications, or supplements. All author names are pseudonyms. Author photographs are stylized portraits, not images of real individuals. See our About page and Disclaimer for full disclosure on editorial policy and anonymity.
